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Background: The Rapid-i is a new FDA cleared closed carrier for embryo vitrification. The cooling rate of - 1220°C/min
is far lower than that reported with open vitrification systems such as the cryoloop (−15,000°C/min). Little published
data is currently available on this device. This study presents our initial clinical data, as well as live birth outcomes, with
the Rapid-i. The efficacy of this device for the cryopreservation of cleavage, as well as blastocyst stage human embryos
is also analyzed. We further compare outcomes to those achieved with the cryoloop, an “open” vitrification system
routinely used in our laboratory.
Methods: Human embryos were vitrified at either the 8–10 cell stage or else the blastocyst stage. The vitrification
protocol was: 7.5% DMSO/7.5% ethylene glycol (EG) (2–3 min) followed by incubation in 15% DMSO /15% EG
(45 sec) before loading on the vitrification carrier. Cryoprotectant was removed during warming by sequential washes
in 0.25 M and 0.125 M sucrose in culture medium. Clinical outcome data for frozen cycles between January 2011 and
August 2012 were stratified according to carrier and cell stage. The student t-test and chi square test were used to
compare results. P value of < 0.05 was considered significant.
Results: A total of 486 vitrified-warmed embryos were assessed and 92% of them were transferred. The clinical
pregnancy rate (CPR) and implantation rate (IR) with Rapid-i vitrified blastocysts were 59% and 49%, versus 47% and
37%, respectively for cleavage stage embryos. This was not statistically different from results with the cryoloop vitrified
blastocysts (CPR 46%, IR 38%) nor the cleavage stage vitrified embryos (CPR 49%, IR 35%). To date, there have been 31
deliveries of 34 healthy infants from Rapid-i vitrified embryos, with another 12 pregnancies still
on-going.
Conclusions: The Rapid-i offers an excellent alternative to existing open vitrification devices for embryo
cryopreservation at the 8–10 cell stage as well as the blastocyst stage. Use of this type of “closed” sealed system that
prevents direct contact between the embryos and liquid nitrogen reduces the potential risk of sample
cross-contamination or infection. These preliminary data and live birth outcomes have paved the way toward
transitioning to a closed vitrification system in our own IVF program.Background
Vitrification is rapidly replacing slow cryopreservation as
the method of choice for embryo freezing in clinics world-
wide. Increasing evidence from published outcomes with
both techniques suggest that vitrification may in fact be
superior to slow cooling [1-7].
In contrast to slow cryopreservation methods, which
use cooling rates of - 0.3°C per minute, vitrification uses* Correspondence: desain@ccf.org
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reproduction in any medium, provided the orrapid cooling rates to preserve the embryo instantan-
eously in a “glass-like state”. Vitrification requires high
concentrations of cryoprotectant combined with high
cooling rates to transition from a fluid to solid state
without a phase change thus avoiding intra or extracellular
ice crystallization [8]. A practical limitation to establishing
successful vitrification protocols has been the achievement
of sufficiently high cooling rates in conventional freezing
vessels [7,9,10]. Developing vessels to sequester the cell in
miniscule fluid volumes, of a microliter or less, has been
one approach to increasing cooling rates.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of different vitrification devices or carriers that can be
classified as either “open” or “closed”. “Open” vitrification
devices allow direct contact of the embryos with liquid
nitrogen. Much of the early work establishing the efficacy
of vitrification, and documenting the first live births, were
performed using open carriers like the cryoloop [11-13],
EM grids [14], Cryotop [15] and open pulled straws
[16-19]. Despite successful use of “open” carriers for
embryo vitrification, direct contact between the embryo
and liquid nitrogen may not be desirable as there is a
potential risk of cross-contamination between speci-
mens or inadvertent exposure to contaminants present
in the tank [20-22]. The use of “closed” vitrification car-
riers circumvents these risks. Examples of closed carrier
systems include; cryotips (Irvine Scientific, CA, USA),
high security vitrification straw (HSV) (Cryo BioSystem,
Paris, France), VitriSafe (VitriMed, Austria) and Cryopette
(Origio, Denmark). Initial concerns that the lower cooling
rates with closed sealed vitrification systems may com-
promise pregnancy outcomes have been dispelled by
recent publications using commercially marketed “closed”
vitrification carriers [2,23-26].
The Rapid-i is a new “closed“ vitrification device,
recently received FDA clearance for embryo vitrification.
The cooling rate of −1220°C/min is far lower than that
reported with other vitrification systems [26,27]. Little
published data is currently available on this new carrier
[28-30]. The present work summarizes our initial clinical
data, as well as live birth outcomes, with the Rapid-i. The
efficacy of this device for the cryopreservation of early, as
well as late stage, human embryos is also analyzed. We
further compare outcomes to those achieved in our
laboratory with an “open” vitrification system, namely the
cryoloop, with its high cooling rate of −15,000°C /min.
Methods
Patients
Embryo vitrification using the Rapid- i carrier was
introduced into our clinical practice in January 2011 for
cryopreservation of day 3 cleavage stage embryos as well
as blastocysts. Prior to this, embryo vitrification was
performed using the cryoloop.
This study examines outcomes from patients ≤40 years
of age returning to the Cleveland Clinic Fertility Center
for a frozen embryo transfer (FET) cycle between January
2011 and August 2012. During this time period, 95
couples returned for an FET cycle with embryos vitrified
with the new Rapid-i carrier. Another 161 couples had an
FET cycle with embryos vitrified prior to 2011 using the
cryoloop carrier. Outcome data was retrospectively ana-
lyzed from our IVF laboratory database registry in accor-
dance with the ethical policy and guidelines set forth by
the Cleveland Clinic’s Institutional Review Board.Ovarian stimulation and IVF
Women were treated with either a GnRH-agonist (go-
nadotropin releasing hormone) or a GnRH-antagonist to
suppress ovulation until follicle maturity was attained.
Ovarian stimulation was initiated using daily injections
of follicle stimulating hormone (FSH) at starting doses
of 225 IU per day or adjusted based on serum anti-
mullerian hormone levels, antral follicle counts and the
response to previous stimulations. Subsequent doses
were adjusted according to transvaginal ultrasonograms
and serum estradiol levels. Final follicular maturation
was triggered with human chorionic gonadotrophin
(hCG) when at least two lead follicles measured 18 mm
in mean diameter. Oocytes were collected 36 hours later
by transvaginal needle aspiration of follicles under ultra-
sound guidance.
Mature oocytes were inseminated by intracytoplasmic
sperm injection 2–4 hours after retrieval. Intermediate
and immature oocytes underwent conventional IVF in-
semination. Oocytes were examined 16–18 hours after
insemination for the presence of two pronuclei. Zygotes
were individually cultured in 20 μl drops of Global
medium (LifeGlobal, Guilford, CT) supplemented with
10% Synthetic Protein Supplement (SPS; Cooper Surgical;
Trumbull, CT) under an oil overlay. All culture was
performed at 37°C with 6% CO2 in air. Fresh embryo
transfers were performed on day 5 for patients with 8 or
more good quality embryos and on day 3 for all other
patients.
Embryo assessment
Embryos were observed and graded daily. Cleavage stage
embryos were assessed for cell stage, percent fragmenta-
tion, multinucleation, blastomere symmetry and degree of
cell:cell adherence. Blastocyst grade was assigned based on
day of blastocyst formation, blastocyst maturity, inner cell
mass development, trophectoderm appearance and degree
of necrosis after warming using a previously described
scoring system [31,32]. Blastocoel volume and expansion
were used to classify blastocysts as: A = early blastocyst,
cavity just starting to form; B = early blastocyst, cavity less
than half the volume of embryo; C = expanded with cavity
greater than half embryo volume; D = fully expanded; and
E = hatching. The inner cell mass was graded as: 0- absent
or not yet visible; 1- sparse, few cells; and 2- well defined,
discrete cell mass. Trophectoderm of the blastocyst was
assessed based on overall cell number and organization:
1- low cell number, stretched appearance; 2- well organized
cohesive cell layer; and 3- extremely high cell number but
well organized.
Embryo cryopreservation was carried out on day 3 at
the cleavage stage or on days 5/6 at the blastocyst stage.
For day 3 cryopreservation, embryos needed to be
between 8–10 cells with even blastomeres and <20%
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kept in extended culture and vitrified if they reached the
blastocyst stage. Patients having a fresh blastocyst transfer
had their supernumerary blastocysts (grades B-E), which
displayed an inner cell mass, cryopreserved on day 5. The
remaining embryos were given an extra day to develop in
culture. In a few patients, morula and early blastocysts
without a clearly visible ICM were cryopreserved if
nothing else was available for cryobanking by day 6.
Vitrification procedure
A two-step vitrification protocol was used for both
cleavage and blastocyst stage embryos [33]. This tech-
nique uses dimethylsulfoxide (DMSO), ethylene glycol
(EG) and sucrose as the cryoprotectant agents (CPA).
Embryos were loaded either singly or in pairs on to the
carrier and vitrified. All vitrification solutions were pre-
pared in-house. Vitrification Solution #1 (VS1) consisted
of 7.5% DMSO and 7.5% EG in Global medium with
20% SPS. Vitrification Solution #2 (VS2) contained 15%
DMSO, 15% EG, 10 mg/ml Ficoll-70 and 0.65 M
sucrose. All incubations steps were performed at 37°C.
Embryos were rinsed and held in VS1 for 2 min (3 min
for blastocysts). Embryos were then quickly moved
through three drops of VS2, holding for 15 sec in each
drop, before loading on the vitrification carrier in use at
the time.
The Rapid-i was prepared for loading in accordance
with the manufacturer’s instructions. The outer straw
with metal rod was immersed in the liquid nitrogen
holding container. The Rapid-i stick with hole was laid
on the lid of a Falcon 1006 dish. A finely drawn glassFigure 1 Comparison of the “closed” Rapid-i carrier to the “open” cry
cooling /warming rates.micropipette was used to pick up 1–2 embryos. The tiny
hole in the Rapid-i stick was visualized using a dissecting
microscope and the embryos were deposited with min-
imal fluid into the hole (Figure 1). The Rapid-i stick with
embryos was quickly dropped into the pre-frozen outer
straw after first removing the metal rod. The outer straw
containing the Rapid-i stick was then quickly sealed with
an ultrasonic sealer. Straws were placed in goblets then
moved to the liquid nitrogen storage tank.
The technique for cryoloop loading involved first pre-
paring a film of cryoprotectant on the loop by dipping in
VS2. The embryos were then quickly loaded on to the
film using a micropipette (Figure 1). Immediately after
loading, the cryoloop with embryos was immersed in a
cryovial containing liquid nitrogen. The magnetic cap
was tightened using a metal wand and the vial was then
moved to the liquid nitrogen storage tank.
Artificial collapse of blastocysts
Artificial shrinkage of fluid volume in blastocysts was
performed to enhance survival. Expanding blastocysts
with a blastocoel encompassing > ½ of the embryo were
artificially collapsed prior to vitrification using an ICSI
needle (Figure 2). The blastocyst was positioned on the
holding pipette such that the inner cell mass was located
at either the 12 or 6 o’clock position. An ICSI needle
was pressed through the trophectoderm at the 3 o’clock
position and advanced about mid way through the
blastocyst. A slight negative pressure was maintained in
the ICSI needle but blastocoelic fluid was not aspirated.
The majority of blastocysts collapsed immediately upon
piercing. The needle was then gently withdrawn. Theoloop. Diagram illustrates the two carriers, properties and compares
Figure 2 Blastocoel reduction using a mechanical technique. Artificial collapse of an expanded blastocyst is shown. (a,b) An ICSI needle is
used to pierce the blastocyst in an area distal to the inner cell mass. (c) Within 5 minutes, blastocoelic fluid has leaked out and blastocoel volume
is reduced. Magnification 300 ×.
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itional shrinkage of the blastocoel before vitrification.
Warming of embryos and assessment of survival
Cryoprotectant was removed by two sequential washes
in warming solutions containing decreasing concentra-
tions of sucrose (0.25 M and 0.125 M) in Global medium
with 20% SPS. All steps were performed at 37°C with
pre-equilibrated solutions. Warming solutions (0.5 ml)
were placed in the center well of two organ culture
dishes. A third wash dish was set up with culture
medium for rinsing.
The Rapid-i straw was placed in a small dewar
containing liquid nitrogen. The straw was cut and the
inner Rapid-i stick with the embryos was firmly grasped,
while still partially submerged in liquid nitrogen. The
Rapid-i stick was then quickly pulled free of the straw and
immersed in the first warming solution (0.25 M sucrose)
and swirled to unload the embryos. The dish was then
carefully examined under the dissecting scope and the
embryos located. After two minutes, the embryos were
moved to the second warming solution (0.125 M sucrose).
After three minutes, the embryos were placed in the wash
dish and incubated for an additional five minutes. Essen-
tially the same procedure was used for warming embryos
vitrified on the cryoloop. The embryos were unloaded by
immersing the cryoloop directly in the first warming
solution.
After the warming steps were completed, cleavage as
well as blastocyst stage embryos underwent assisted hatch-
ing using a 1.48 μm diode laser. Two to three laser pulses
were delivered to open the zona. The embryos were then
transferred to a culture dish and examined under an
inverted microscope at 400× magnification to assess for
signs of cryoinjury and blastomere damage. Cleavage stage
embryos were considered to have “survived” if at least
half of the blastomeres were intact. Following warming,
cleavage embryos were cultured for 48 hours to confirm
continued developmental competency.
Cryosurvival of vitrified- warmed blastocysts, was
determined on the basis of morphology immediately
after warming. Blastocysts with dark, granular appearingcells and large areas of degeneration were identified as
“non-surviving”. Warmed blastocysts were incubated for
2 hours and re-examined before transfer. Blastocoel ex-
pansion, trophectoderm organization and inner cell mass
presence and cohesiveness were once again scored. A
photographic record was kept of embryo morphology
immediately after warming and just before transfer.
After assessment of morphology, the embryos were
moved to an organ culture dish containing Embryo Glue
(VitroLife; Englewood, Colorado) in preparation for the
transfer procedure.
Embryo transfer and pregnancy assessment
Patients were prepared for frozen embryo transfer using
endometrial priming with daily oral estradiol (6 mg)
beginning on cycle day 1 and intramuscular (IM) proges-
terone (50–100 mg) starting on day 13. The endometrial
lining was monitored for thickness and trilaminar ap-
pearance before starting progesterone therapy. Cycles
were cancelled if the endometrial thickness was <7 mm.
Transfer of vitrified-warmed blastocysts was performed
after 6 days of progesterone treatment. Cleavage stage vit-
rified embryos were replaced after 5 days of progesterone.
Embryo transfer was performed under transabdominal
ultrasound guidance using a Wallace Sure-View catheter.
Progesterone was continued for luteal support. Serum
hCG levels were measured 15 days after transfer to detect
pregnancy. A clinical pregnancy was confirmed by
visualization of an intrauterine gestational sac with fetal
heart activity on ultrasound 4 weeks after the embryo
transfer. The implantation rate (IR) was calculated by
dividing the number of gestational sacs by the number
of embryos transferred. Ongoing pregnancy was defined
as pregnancies continuing past 12 weeks gestation.
Outcome parameters and data analysis
Outcome measures monitored were embryo survival
(>50% intact), morphology at transfer, clinical pregnancy
rate per transfer (CPR) and implantation rate. Clinical
outcome data for frozen cycles between January 2011
and August 2012 were stratified according to carrier and
cell stage. For data analysis, blastocyst FET cycles were
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transferred embryos post-warming. Embryos vitrified at
the cleavage stage were monitored for resumption of
mitosis, genomic activation and blastulation during the
48 hour culture interval before transfer. The student t-test,
chi square test and Fischer’s exact test were used as
appropriate to compare outcome parameters. Data is
expressed as mean ± SD (standard deviation). P values
of <0.05 were considered to be statistically significant.
Statistical analysis was performed using the software
Stats Direct (Cheshire, UK).
Results
This study compared our initial results with the Rapid-i
vitrification carrier to those achieved with our standard
cryoloop method. Table 1 summarizes the results from
vitrification-warming cycles with the Rapid-i (n = 95)
and the cryoloop (n = 161). A total of 486 vitrified-
warmed embryos were assessed and 92% of them were
transferred. The data in the table is separated into four
groups according to carrier and cell stage at vitrification.
Patient ages in the four treatment groups were similar.
The clinical pregnancy and implantation rates with
cleavage stage embryos vitrified on the Rapid-i (47% and
37%, respectively) were comparable to those obtained
with the cryoloop (49% and 36%, respectively). The
mean number of embryos warmed with Rapid-i and
cryoloop was also similar (2.14 ± 0.71 and 2.01 ± 0.44,
respectively). After warming, 99% of the embryos in bothTable 1 Comparison of vitrification outcomes for day 3 cleava
Stage at Vitrification Clea
Rapid-i
Patient age 33.6 ± 3.3
No vitrification-warming cycles 44
No. vitrified embryos warmed 92
No. intact embryos on warming (%) 91(99)
Mean no. embryos thawed 2.1 ± 0.7
No. transfers 43
No. embryos surviving and transferred 85
Mean no. embryos transferred 2.0 ± 0.5
Implantation rate (%) 31/85 (37)
Clinical pregnancy rate (%) 20/43(47)
Multiple pregnancy rate (%) 2/20 (10)





No significant differences between carriers for vitrification at either cell stage.
Data expressed as mean ± SD.groups had 50% or more of their blastomeres intact.
To date, we have had 15 deliveries of 16 healthy infants
(8 boys and 8 girls) from Rapid-i vitrified cleavage
stage embryos, with 3 pregnancies still on-going and 2
miscarriages. The percentage of pregnancies proceed-
ing beyond 12 weeks gestation was 42% with the
Rapid-i which was not significantly different from
those with the cryoloop (44%). Resumption of mitosis
after warming and the continued development of the
8–10 cell embryos during the 48 hour in vitro culture
interval was prognostic of positive outcomes. In FET
cycles where at last one of the cleavage stage embryos
advanced to the expanded blastocyst stage, the CPR and
IR in the Rapid-i treatment group were 67% (14/21) and
54% (22/41), respectively. In comparison, if embryos only
reached the morula or early blastocyst stage, there was a
marked decrease in both CPR (27%, 6/22 ) and IR (23%, 9/
40), respectively (p < 0.05). A similar association between
in vitro growth and outcome measures was observed with
cryoloop vitrified day 3 embryos. Outcomes were signifi-
cantly compromised when only early blastocysts/morula
were available for transfer (CPR 33%, 15/45; IR 18%,
15/84) versus FET cycles with expanded/hatched blastocysts
(CPR 76%, 19/25; IR 69%, 31/45; p < 0.05). Figure 3 illus-
trates typical morphology of vitrified 8-cell embryos 24
and 48 hours after warming.
Outcomes with blastocyst vitrification on the Rapid-i
appeared somewhat higher than those achieved with
cryoloop but the differences did not reach statisticalge and blastocyst stage embryos using different carriers
vage Blastocyst
Cryoloop Rapid-i Cryoloop
34.1 ± 3.7 34.2 ± 3.8 34. ± 3.2
71 51 90
139 92 163
137 (99) 89 (97) 148 (91)
2.0 ± 10.4 1.8 ± 0.7 1.8 ± 0.7
70 51 85
130 88 143
1.9 ± 0.4 1.7 ± 0.5 1.7 ± 0.5
46/130 (35) 43/88 (49) 54/143(38)
34/70 (49) 30/51 (59) 39/85 (46)
10/34 (29) 8/30 (27) 9/39 (23)





Figure 3 Development of Rapid-i vitrified –warmed embryos. Images of human embryos vitrified on Day 3 at the 8–10 cell stage using the
Rapid-i carrier (a,b) Morphology immediately after warming, (c,d) Morphology after 24 hours of culture. Both embryos show signs of embryonic
compaction and resumption of mitosis, (e,f) Embryos progressed to the blastocysts stage after 48 hours in culture. Transfer resulted in a twin
pregnancy. Magnification 300 ×.
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46%, respectively; p = 0.199 and the implantation rates
were 49% vs. 38 %; p = 0.128. The mean number of
embryos warmed was 1.8 for both treatment groups.
The survival rate of vitrified blastocysts was 97% with
the Rapid-i versus 91% with the cryoloop (p = 0.07).
Transfer of Rapid-i vitrified blastocysts has to date
resulted in the birth of 18 healthy babies (9 boys and 9
girls), with 9 pregnancies still-ongoing and 5 miscar-
riages. Once again, the on-going pregnancy rate did not
differ from that observed with cryoloop vitrification
(49% vs. 39%).
Blastocyst expansion and size of the blastocoel cavity
were morphologic features closely linked to successful
implantation of vitrified-warmed blastocysts. Blastocysts
with high implantation potential appeared completely
collapsed when recovered from the vitrification device
and expanded by the time of transfer as shown in
Figure 4.
The clinical pregnancy rate and implantation data for
varying qualities of embryos are presented in Figure 5.
Transfers were grouped according to the morphology of
the embryos 2 hours after warming. With the Rapid-i,
66% of expanded/hatched blastocysts (19/29) implanted
and the CPR was 80% (16/20). In contrast, both the CPR
and IR were significantly lower with early blastocysts,
47% (7/15) and 38% (10/26), respectively (p < 0.05). This
difference between outcomes from advanced versus early
blastocyts was not observed with cryoloop vitrified blas-
tocysts. The clinical pregnancy rates were 53% (10/19)vs. 50% (9/18), respectively and implantation rates were
43% (13/30) vs. 30% (9/30), respectively. Regardless of
vitrification carrier, the prognosis for patients with only
morula or non re-expanded blastocysts for transfer was
distinctly poorer with the implantation rates per embryo
being 14% (1/7) for Rapid-i and 9.7% (3/31) for
cryoloop.
Discussion
The Rapid-i is a brand new vitrification carrier and this
is one of the first clinical studies documenting its effi-
cacy with human embryos at both early and late devel-
opmental stages. This is also the first report on live birth
rates with the Rapid-i. The impact of the lower cooling
rate during vitrification was of particular concern to us,
especially as it relates to different embryonic stages and
blastomere cell size. Our data however clearly indicate
that the Rapid-i carrier can be effectively applied to both
early cleavage as well as blastocyst stage embryos.
The basic premise underlying the design of new
vitrificaton systems and carriers has, to date, been fo-
cused on achieving high cooling rates. As pointed out by
Seki and Mazur [34], cryoinjury may in fact be more
related to recrystallization during warming rather than
the failure to vitrify. In that study, the authors examined
the relationship between cooling versus warming rates
and vitrification results with mouse oocytes. They con-
cluded that a warming rate of at least 3000°C/min was
necessary to achieve 80% survival. Moreover, their data
indicated that if the warming was quick enough, a
Figure 4 Blastocyst stage vitrification and re-expansion after warming. Human blastocysts vitrified with the Rapid-i. (a,b) Morphology
immediately after warming, (c,d) Morphology two hours later. Both blastocysts now fully expanded and hatching out from the opening in the
zona created after warming. Transfer resulted in a singleton pregnancy. Magnification 300 ×.
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for successful vitrification.
Our present data with human embryos certainly concurs
with the relative importance of the warming over the
cooling rate. The warming temperature of 7700°C/min
with the Rapid-i was clearly sufficient to give outcomes
comparable to an open system like the cryoloop, despite a
15-fold lower cooling rate of −1220°C/min. The 59% CPR
and 49% implantation rate achieved with Rapid-i blasto-
cyst vitrification closely parallels pregnancy outcomes
from fresh single embryo transfer of blastocysts at our IVF
center (unpublished results). We also found that the lower
cooling rate with the Rapid-i was not a deterrent to
successful vitrification of day 3 cleavage embryos despite
the larger size of the individual blastomeres. According to
the SART (Society for Assisted Reproductive Technology)
registry’s 2011 national summary data, young patients
under 35 having a fresh transfer had a 36% implant-
ation rate. It was reassuring that we were able toachieve this same implantation rate with Rapid-i vitri-
fied 8-cell embryos.
Concerns have been raised regarding the safety of
open vitrification carriers for the cryopreservation of re-
productive cells [2,20-22,35]. Although, there have been
no reported incidents of human reproductive tissue con-
tamination during storage in liquid nitrogen tanks to
date, there has been a movement toward the use of
“closed” sealed systems for human gamete/embryo cryo-
preservation. The long-standing argument for use of
open systems has been that the benefit of higher cooling
rates and ease of embryo loading/recovery far outweigh
the theoretical risks of using such and open system. This
former objection is rapidly becoming obsolete with accu-
mulating pregnancy outcome data from closed vitrifica-
tion carriers [6]. The current data set provides further
evidence to suggest that a closed vitrification carrier can
be used effectively for embryos at both early and late
stages. Despite the far lower cooling and warming rates
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Figure 5 Blastocyst morphology after warming and clinical outcomes. Graph depicts relationship between embryo morphology and clinical
outcomes in blastocyst (BL) vitrification-warming cycles. Embryos were graded as expanded blastocysts (EBL), early blastocysts, morula (Mor) or
non re-expanded blastocysts (NR). Transfers were divided in to four general groups based on carrier used for vitrification and the morphology of
the transferred embryos: 1-EBL only, 2-EBL/ Early BL (transfers with mixed stages), 3-Early BL only and 4-Mor/NR. Relationship between embryo
morphology at transfer and resultant CPR and IR was examined. The number of transfers for each group and respective carrier is shown on the
graph. Bars depict percent of transfers resulting in clinical pregnancy (CPR) and percent of embryos implanting (IR). * P < 0.05 CPR and IR for
Rapid-i Group 1 vs. Groups 3 and 4 ** P < 0.05 CPR and IR for Cryoloop Group 1 vs. Group 4.
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to the HSV straw (−2900°C/min, +25,000°C/min) [26,27],
clinical outcomes more than matched those with the HSV
(CPR 45%, IR 31%) [23]. Transitioning to the Rapid-i
closed carrier was aided by its clever design. Its resem-
blance to the cryoloop as far as embryo loading and
recovery made it technically easy to use.
It should be noted that with cryopreservation at the
blastocyst stage, it was important to critically assess the
degree of expansion and alter the vitrification protocol
accordingly. Blastocyst collapse was integral to success-
ful vitrification of expanded blastocysts. Cell death and
DNA damage is lower if the size of the blastocoelic cav-
ity is reduced prior to vitrification [36]. Vanderzwalmen
and colleagues first described the benefit of blastocoel
shrinkage to improve cryosurvival [18]. A variety of
methods have been applied to reduce blastocoelic vol-
ume prior to vitrification leading to improvements in
post-warming survival and ultimately, clinical outcomes
[14,15,18,37,38]. Mukaida and colleagues reported an
implantation rate of 47% with mechanically or laser col-
lapsed blastocysts vitrified on cryoloops [37]. We had a
similarly high 49% implantation rate with mechanically
collapsed blastocysts cryopreserved using the the Rapid-i
closed vitrification system. In contrast, Hashimoto et al.
vitrified blastocysts on the Rapid-i without collapsing
and reported clinical outcomes similar to our own [29].
It is likely that the specific vitrification protocol in com-
bination with the type of carrier and the morphology of
the blastocyst being cryopreserved may dictate whether
or not collapsing is necessary.Conclusions
In summary, the Rapid-i offers an excellent alternative
to existing open vitrification devices for embryo cryo-
preservation at the 8–10 cell stage as well as at the
blastocyst stage. Use of this type of “closed” system that
prevents direct contact between the embryos and liquid
nitrogen reduces the potential risk of sample cross-
contamination or infection. These preliminary data and
live birth outcomes have paved the way toward
transitioning to a closed vitrification system in our own
IVF program. The ease of embryo loading and
unloading played an important role in the selection and
acceptance of this particular device as opposed to other
commercially available closed vitrification devices. Add-
itional data from other centers are needed to further
corroborate these findings.Competing interests
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